Bioradiotherapy For Head And Neck Cutaneous Squamous Cell Carcinoma.

6038 Background: Locally advanced, high-risk head and neck cutaneous squamous cell carcinomas (CSCC) are typically aggressive. We sought to compare treatment tolerability, disease control and survival between radiotherapy alone and radiotherapy plus cetuximab in CSCC patients. Methods: Patients diagnosed with high-risk CSCC based on NCCN criteria between 2006-2013 were included. Patients were divided into two groups: radiotherapy alone versus radiotherapy plus cetuximab. Primary analysis examined disease-free and overall survival, freedom from local and distant recurrence in the propensity score matched cohort. Propensity score analysis was performed with weighted factors including: Charlson Comorbidity Index score (age-adjusted), age. KPS, primary location, T and N stage, recurrent status, margin status, LVSI, PNI and grade. Toxicity was assessed using the CTCAE v4.0. Results: Among 68 patients meeting study criteria, we identified 29 treated with cetuximab plus RT and 39 with RT alone. Median follow-up ...